DESCRIPTION

Alpha₁–Proteinase Inhibitor (Human), Aralast™, is a sterile, stable, lyophilized preparation of purified human alpha₁–proteinase inhibitor (α₁–PI), also known as alpha₁–antitrypsin.¹

Aralast™ is prepared from large pools of human plasma by using the Cohn–Oncley cold alcohol fractionation process, followed by purification steps including polyethylene glycol and zinc chloride precipitations and ion exchange chromatography. To reduce the risk of viral transmission, the manufacturing process includes treatment with a solvent detergent (SD) mixture [tri–n–butyl phosphate and polysorbate 80] to inactivate enveloped viral agents such as HIV and Hepatitis B and C. In addition, a nanofiltration step is incorporated prior to final sterile filtration to reduce the risk of transmission of non–enveloped viral agents. Based on in vitro studies, the process used to produce Aralast™ has been shown to inactivate and/or partition various viruses as shown in the table below.²

<table>
<thead>
<tr>
<th>Processing Step</th>
<th>Elimination of Deliberately Added Virus (Number of logs inactivated/removed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV–1</td>
</tr>
<tr>
<td>Alcohol Fractionation</td>
<td>≥ 4.8</td>
</tr>
<tr>
<td>Solvent Detergent Treatment</td>
<td>≥ 7.2</td>
</tr>
<tr>
<td>Nanofiltration</td>
<td>N/A</td>
</tr>
<tr>
<td>Accumulated Reduction</td>
<td>≥ 12.0</td>
</tr>
</tbody>
</table>

* HIV–1: Fractionation units log₁₀ SFU SD Treatment units log₁₀ TCID₅₀/mL
† BVD (Bovine Viral Diarrhea), PRV (Pseudorabies Virus): SD Treatment units log₁₀ PFU/mL, Nanofiltration units log₁₀ PFU
‡ HAV (Hepatitis A), PPV (Porcine Parvovirus) Nanofiltration units log₁₀ PFU
N/A Not Applicable
When reconstituted as directed, the concentration of $\alpha_1$–PI is not less than 16 mg/mL and the specific activity is not less than 0.55 mg active $\alpha_1$–PI/mg total protein. The composition of the reconstituted product is as follows:

<table>
<thead>
<tr>
<th>Component</th>
<th>Quantity/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elastase Inhibitory Activity</td>
<td>NLT 400 mg Active $\alpha_1$–PI/0.5 g vial *</td>
</tr>
<tr>
<td></td>
<td>NLT 800 mg Active $\alpha_1$–PI/1.0 g vial **</td>
</tr>
<tr>
<td>Albumin</td>
<td>NMT 5 mg/mL</td>
</tr>
<tr>
<td>Polyethylene Glycol</td>
<td>NMT 112 µg/mL</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>NMT 50 µg/mL</td>
</tr>
<tr>
<td>Sodium</td>
<td>NMT 230 mEq/L</td>
</tr>
<tr>
<td>Tri–n–butyl Phosphate</td>
<td>NMT 1.0 µg/mL</td>
</tr>
<tr>
<td>Zinc</td>
<td>NMT 3 ppm</td>
</tr>
</tbody>
</table>

NLT: Not Less Than  
NMT: Not More Than  
* Reconstitution volume: 25 mL/0.5 g vial  
** Reconstitution volume: 50 mL/1.0 g vial

Each vial of Aralast™ is labeled with the amount of functionally active $\alpha_1$–PI expressed in mg/vial. The formulation contains no preservative. The pH of the solution ranges from 7.2 to 7.8. Product must only be administered intravenously.

**CLINICAL PHARMACOLOGY**

$\alpha_1$–Proteinase Inhibitor (Human), Aralast™, functions in the lungs to inhibit serine proteases such as neutrophil elastase (NE), which is capable of degrading protein components of the alveolar walls and which is chronically present in the lung. In the normal lung, $\alpha_1$–PI is thought to provide more than 90% of the anti–NE protection in the lower respiratory tract.

$\alpha_1$–PI deficiency is an autosomal, co-dominant, hereditary disorder characterized by low serum and lung levels of $\alpha_1$–PI. Severe forms of the deficiency are frequently associated with slowly progressive, moderate-to-severe panacinar emphysema that most often manifests in the third to fourth decades of life, resulting in a significantly lower life expectancy. Individuals with $\alpha_1$–PI deficiency have little protection against NE released by a chronic, low-level of neutrophils in their lower respiratory tract, resulting in a protease:protease inhibitor imbalance in the lung. The emphysema associated with $\alpha_1$–PI deficiency is typically worse in the lower lung zones. It is believed to develop because there are insufficient amounts of $\alpha_1$–PI in the lower respiratory tract to inhibit NE. This imbalance allows unopposed destruction of the connective tissue framework of the lung parenchyma.

There are a large number of phenotypic variants of this disorder. Individuals with the PiZZ variant typically have serum $\alpha_1$–PI levels less than 35% of the average normal level. Individuals with the Pi(null)(null) variant have undetectable $\alpha_1$–PI protein in their serum. Individuals with these low serum $\alpha_1$–PI levels, i.e., less than 11 µmolar (80 mg/dL), have an unknown risk of developing emphysema over their lifetimes. Two Registry studies have shown risks of 54.2 and 57.0%. The risk of accelerated
development and progression of emphysema in individuals with severe α₁−PI deficiency is higher in smokers than in ex-smokers or non-smokers. The deficiency in α₁−PI represents one of the most common, potentially lethal hereditary disorders.4

A clinical study was conducted to compare Aralast™ (test drug) to a commercially available preparation of α₁−PI (Prolastin®), manufactured by Bayer Corporation. All subjects were to have been diagnosed as having congenital α₁−PI deficiency and emphysema but no α₁−PI augmentation therapy within the preceding six months.

Twenty-eight subjects were randomized to receive either test drug or control drug, 60 mg/kg intravenously per week, for 10 consecutive weeks. Two subjects withdrew from the study prematurely: 1 subject receiving Aralast™ withdrew consent after 6 infusions; 1 subject receiving Prolastin® withdrew after 1 infusion due to pneumonia following unscheduled bronchoscopy to remove a foreign body. Trough levels of serum α₁−PI (antigenic determination) and anti−NE capacity (functional determination) were measured prior to treatment at Weeks 8 through 11. Following their first 10 weekly infusions, the subjects who were receiving control drug were switched to Aralast™ while those who already were receiving Aralast™ continued to receive it. Maintenance of mean serum α₁−PI trough levels was assessed prior to treatments at Weeks 12 through 24. Bronchoalveolar lavages (BALs) were performed on subjects at baseline and prior to treatment at Week 7. The ELF from each BAL meeting acceptance criteria was analyzed for the α₁−PI level and anti−NE capacity.

With weekly augmentation therapy, a gradual increase in peak and trough serum α₁−PI levels was noted, with stabilization after several weeks. The metabolic half−life of Alpha₁−Proteinase Inhibitor (Human), Aralast™, was 5.9 days. Serum anti−NE capacity trough levels rose substantially in all subjects by Week 2, and by Week 3, serum anti−NE capacity trough levels exceeded 11 µM in the majority of subjects. With few exceptions, levels remained above this recommended threshold level in individual subjects for the duration of the period Weeks 3 through 24 on study. Although only five of fourteen subjects (35.7%) receiving Aralast™ had BALs meeting acceptance criteria for analysis at both baseline and Week 7, a statistically significant increase in the antigenic level of α₁−PI in the ELF was observed. No statistically significant increase in the anti−NE capacity in the ELF was detected.

Viral serology of all subjects was determined periodically throughout the study, including testing for antibodies to hepatitis A (HAV) and C (HCV), presence of circulating HBsAg, and presence of antibodies to HIV−1, HIV−2, and Parvovirus B−19. Subjects who were seronegative to parvovirus B−19 at enrollment were retested by PCR at Week 2. There were no seroconversions in subjects treated with Aralast™ through Week 24. None of the subjects became HBsAg positive during the study, although five of 13 (38%) evaluable subjects in the test group and eight of 13 (62%) in the control group had not been vaccinated to hepatitis B. No patient developed antibodies against α₁−PI.

It was concluded that at a dose of 60 mg/kg administered intravenously once weekly, Aralast™ and the control α₁−PI preparation had similar effects in maintaining target serum α₁−PI trough levels and increasing antigenic levels of α₁−PI in epithelial lining fluid (ELF) with maintenance augmentation therapy.
INDICATIONS AND USAGE

Congenital Alpha₁-Proteinase Inhibitor deficiency

Alpha₁-Proteinase Inhibitor (Human), Aralast™, is indicated for chronic augmentation therapy in patients having congenital deficiency of α₁-PI with clinically evident emphysema. Clinical and biochemical studies have demonstrated that with such therapy, Aralast™ is effective in maintaining target serum α₁-PI trough levels and increasing α₁-PI levels in epithelial lining fluid (ELF). Clinical data demonstrating the long–term effects of chronic augmentation or replacement therapy of individuals with Aralast™ are not available.

Safety and effectiveness in pediatric patients have not been established. Aralast™ is not indicated as therapy for lung disease patients in whom congenital α₁-PI deficiency has not been established.

CONTRAINDICATIONS

Aralast™ is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA, since they may experience severe reactions, including anaphylaxis, to IgA which may be present.

WARNINGS

Because Alpha₁–Proteinase Inhibitor (Human), Aralast™, is derived from pooled human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent. Stringent procedures designed to reduce the risk of adventitious agent transmission have been employed in the manufacture of this product, from the screening of plasma donors and the collection and testing of plasma through the application of viral elimination/reduction steps such as alcohol fractionation, PEG precipitation, solvent detergent treatment, and nanofiltration. Despite these measures, such products can still potentially transmit disease; therefore, the risk of infectious agents can not be totally eliminated. ALL infections thought by a physician possibly to have been transmitted by this product should be reported to the manufacturer at 1–888–675–2762 (US) or 1–323–225–9735 (International). The physician should weigh the risks and benefits of the use of this product and should discuss these with the patient.

The rate of administration specified in DOSAGE AND ADMINISTRATION should be closely followed, at least until the physician has had sufficient experience with a given patient. Vital signs should be monitored continuously and the patient should be carefully observed throughout the infusion. IF ANAPHYLACTIC OR SEVERE ANAPHYLACTOID REACTIONS OCCUR, THE INFUSION SHOULD BE DISCONTINUED IMMEDIATELY. Epinephrine and other appropriate supportive therapy should be available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PRECAUTIONS

General

Alpha₁-Proteinase Inhibitor (Human), Aralast™, should be administered within three (3) hours after the reconstituted product is warmed to room temperature. Partially used vials should be discarded and not saved for future use. The solution contains no preservative.
Aralast™ should be administered alone, without mixing with other agents or diluting solutions.

Pregnancy Category C
Animal reproduction studies have not been conducted with Aralast™. It is also not known whether Aralast™ can cause fetal harm when administered to pregnant women or can affect reproductive capacity.

Nursing Mothers
It is not known whether alpha_1-proteinase inhibitor is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Aralast™ is administered to a nursing woman.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Aralast™ was evaluated for up to 96 weeks in 27 subjects with a congenital deficiency of α_1-PI and clinically evident emphysema. The number of subjects with an adverse event, regardless of causality, was 22 of 27 (81.5%). The number of subjects with an adverse event deemed possibly, probably, or definitely related to study drug was 7 of 27 (25.9%).

The frequency of infusions associated with an adverse event, regardless of causality, was 108 of 1127 (9.6%) infusions administered per protocol. The most common symptoms were pharyngitis (1.6%), headache (0.7%), and increased cough (0.6%). Symptoms of bronchitis, sinusitis, pain, rash, back pain, viral infection, peripheral edema, bloating, dizziness, somnolence, asthma, and rhinitis were each associated with ≥ 0.2% of infusions. All symptoms were mild to moderate in severity.

The overall frequency of adverse events deemed to be possibly, probably, or definitely related to study drug was 15 of 1127 (1.3%) infusions. The most common symptoms included headache (0.3%) and somnolence (0.3%). Symptoms of chills and fever, vasodilation, dizziness, pruritus, rash, abnormal vision, chest pain, increased cough, and dyspnea were each associated with one (0.1%) infusion. Five (5) of 27 (18.5%) subjects experienced eight (8) serious adverse reactions during the study. None of these were considered to be causally related to the administration of Aralast™.

Twenty-six (26) of 27 (96.3%) subjects experienced a total of 94 upper and lower respiratory-tract infections during the 96-week study (median: 3.0; range: 1 – 8; mean ± SD: 3.6 ± 2.3 infections). Twenty-eight (29.8%) of the respiratory infections occurred in 19 (70.4%) subjects during the first 24 weeks of the 96-week study suggesting that the risk of infection did not change with time on Aralast™. In a post-hoc analysis, subjects experienced a range of 0 to 8 exacerbations of COPD over the 96-week study with a median of less than one exacerbation per year (median: 0.61; mean ± SD: 0.83 ± 0.87 exacerbations per year).

Treatment-emergent elevations (> two times the upper limit of normal) in aminotransferases (ALT or AST), up to 3.7 times the upper limit of normal, were noted in 3 of 27 (11.1%) subjects. Elevations were transient lasting three months or less. No
subject developed any evidence of viral hepatitis or hepatitis seroconversion while being treated with Aralast™, including 13 evaluable subjects who were not vaccinated against hepatitis B.

No clinically relevant alterations in blood pressure, heart rate, respiratory rate, or body temperature occurred during infusion of Aralast™. Mean hematology and laboratory parameters were little changed over the duration of the study, with individual variations not clinically meaningful.

During the initial 10 weeks of the study, subjects were randomized to receive either Aralast™ or a commercially available preparation of α₁-PI (Prolastin®). Both products were well tolerated with the frequency, severity, and symptomatology of adverse reactions similar in both groups. There were no serious adverse events in the group receiving Aralast™. There were two serious adverse events in the control group, one of which was considered to be possibly related to the control drug and included chest pain, dyspnea, and bilateral pulmonary infiltrates. In addition, one subject in the control group became seropositive to Parvovirus B-19. No seroconversions were observed during the entire 96 week study that were attributable to Aralast™. No subject developed an antibody to α₁–PI.

**DOSAGE AND ADMINISTRATION**

**Chronic Augmentation Therapy**

FOR INTRAVENOUS USE ONLY. The recommended dosage of Aralast™ is 60 mg/kg body weight administered once weekly by intravenous infusion. Each vial of Aralast™ has the functional activity, as determined by inhibition of porcine pancreatic elastase, stated on the label. Administration of Aralast™ within three hours after reconstitution is recommended to avoid the potential ill effect of any inadvertent microbial contamination occurring during reconstitution. Discard any unused contents.

**Infusion Rate**

Aralast™ should be administered at a rate not exceeding 0.08 mL/kg body weight/minute. If adverse events occur, the rate should be reduced or the infusion interrupted until the symptoms subside. The infusion may then be resumed at a rate tolerated by the subject.

**RECONSTITUTION**

**Use Aseptic Technique**

1. Aralast™ and diluent should be at room temperature before reconstitution.
2. Remove caps from the diluent and product vials.
3. Swab the exposed stopper surfaces with alcohol.
4. Remove cover from one end of the double–ended transfer needle. Insert the exposed end of the needle through the center of the stopper in the DILUENT vial.
5. Remove plastic cap from the other end of the double–ended transfer needle now seated in the stopper of the diluent vial. To reduce any foaming, invert the vial of diluent and insert the exposed end of the needle through the center of the stopper in the PRODUCT vial at an angle, making certain that the diluent vial is always above the product vial. The angle of insertion directs the flow of diluent against the side of the product vial. Refer to Figure below. The vacuum in the vial is sufficient to allow transfer of all of the diluent.
6. Disconnect the two vials by removing the transfer needle from the diluent vial stopper. Remove the double–ended transfer needle from the product vial and discard the needle into the appropriate safety container.

7. Let the vial stand until most of the contents is in solution, then GENTLY swirl until the powder is completely dissolved. Reconstitution requires no more than five minutes for a 0.5 gram vial and no more than 10 minutes for a 1.0 gram vial.

8. **DO NOT SHAKE THE CONTENTS OF THE VIAL. DO NOT INVERT THE VIAL UNTIL READY TO WITHDRAW CONTENTS.**

9. Use within three hours of reconstitution.

10. After reconstitution, inspect product visually for particulate matter and discoloration prior to administration. When reconstitution procedure is strictly followed, a few small particles may occasionally remain. These will be removed by the microaggregate filter.

11. Reconstituted product from several vials may be pooled into an empty, sterile IV solution container by using aseptic technique. A sterile, 20 micron filter spike is provided for this purpose.

**HOW SUPPLIED**

Alpha\textsubscript{1}-Proteinase Inhibitor (Human), Aralast \textsuperscript{TM}, is supplied as a sterile, non-pyrogenic, lyophilized powder in single–dose vials. A suitable volume of Sterile Water for Injection, USP diluent is provided (25 mL/0.5 g vial; 50 mL/1.0 g vial). Each vial is labeled with the total \(\alpha_1\)–PI functional activity in mg. Aralast\textsuperscript{TM} is packaged with a sterile double–ended transfer needle and a sterile 20 micron filter.

**STORAGE**

Aralast\textsuperscript{TM} should be stored at 2-8 °C (35-46 °F). Aralast\textsuperscript{TM} may be removed from refrigeration and stored at temperatures not to exceed 25 °C (77 °F). Product removed from refrigeration must be used within one month. Do not freeze. Do not use after the expiration date printed on the label.

Rx only

**REFERENCES:**

2. Data on file at Alpha Therapeutic Corporation.

DATE OF REVISION: December 2002
Manufactured and Distributed by:

(Alpha logo and address)

© 2002 Alpha Therapeutic Corporation
Printed in USA
08-8127